Five years after Harvard researchers first received institutional permission to attempt to produce stem cell lines via somatic cell nuclear transfer (SCNT), a young scientist who worked in the Harvard program as a postdoctoral fellow has succeeded in using the process — known as therapeutic cloning — to produce a stem cell line containing the genes of a patient with type 1 diabetes.
In papers in Nature, Nature Communications, and Cell Stem Cell, that scientist, who is now at the independent New York Stem Cell Foundation (NYSCF) laboratory, and Harvard researchers, report on the SCNT advance. In addition, they report on an experiment explaining why other attempts at
And now there are three: in the wake of announcements from laboratories in Oregon and California that they had created human embryos by cloning cells of living people, a lab in New York announced on Monday that it had done that and more.
In addition to cloning the cells of a woman with diabetes, producing embryos and stem cells that are her perfect genetic matches, scientists got the stem cells to differentiate into cells able to secrete insulin.
That raised hopes for realizing a long-held dream of stem cell research, namely, creating patient-specific replacement cells for people with diabetes, Parkinson’s disease,
In the debate on embryonic stem cell research, or its regulations, it seems that the wind is changing both in the US, where President Obama has just changed the rigid guidelines laid out by his predecessor George W. Bush, and in Austria. “There was no pre-arranged organization, however, we were not against it,” said Christiane Druml, the president of the Bioethical Commission, presenting their new recommendations on March 23. A large majority, “including 17 out of 25 women”, believe that embryonic stem cell research is “scientifically relevant, morally legitimate, and worthy of support” and recommended
The capacity to reprogram adult patient cells into pluripotent, embryonic-like, stem cells by nuclear transfer has been reported as a breakthrough by scientists from the US and the Hebrew University of Jerusalem.
The work, described in the journal Nature, was accomplished by researchers from the New York Stem Cell Foundation Research Institute and Columbia University and by Nissim Benvenisty, the Herbert Cohn professor of Cancer Research and director of the Stem Cell Unit at the Institute of Life Sciences at the Hebrew University of Jerusalem, and his graduate student Ido Sagi. The latter assisted in the characterization of the pluripotent
Regenerative medicine took a step forward on Monday with the announcement of the creation of the first disease-specific line of embryonic stem cells made with a patient’s own DNA (…)
“This is a really important step forward in our quest to develop healthy, patient-specific stem cells that can be used to replace cells that are diseased or dead,” said Susan Solomon, chief executive officer of NYSCF, which she co-founded in 2005 partly to search for a cure for her son’s diabetes.
Stem cells could one day be used to treat not only diabetes but also other diseases, such as Parkinson’s and